Journal
CANCER RESEARCH
Volume 73, Issue 15, Pages 4781-4790Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-0566
Keywords
-
Categories
Funding
- Concern Foundation
- Cochrane-Weber endowed Fund in Diabetes Research
- Children's Hospital of Pittsburgh of UPMC
- NIH [5R01EY019721]
Ask authors/readers for more resources
Hypoxia promotes angiogenesis, proliferation, invasion, and metastasis of pancreatic cancer. Essentially, all studies of the hypoxia pathway in pancreatic cancer research to date have focused on fully malignant tumors or cancer cell lines, but the potential role of hypoxia inducible factors (HIF) in the progression of premalignant lesions has not been critically examined. Here, we show that HIF2 alpha is expressed early in pancreatic lesions both in human and in a mouse model of pancreatic cancer. HIF2 alpha is a potent oncogenic stimulus, but its role in Kras-induced pancreatic neoplasia has not been discerned. We used the Ptf1aCre transgene to activate Kras(G12D) and delete Hif2 alpha solely within the pancreas. Surprisingly, loss of Hif2 alpha in this model led to markedly higher, rather than reduced, number of low-grade pancreatic intraepithelial neoplasia (mPanIN) lesions. These lesions, however, failed to progress to high-grade mPanINs, and displayed exclusive loss of beta-catenin and SMAD4. The relationship among HIF2 alpha, beta-catenin, and Smad4 was further confirmed in vitro, where silencing of Hif2 alpha resulted in reduced beta-catenin and Smad4 transcript levels. Thus, with oncogenic Ras expressed in the pancreas, HIF2 alpha modulates Wnt-signaling during mPanIN progression by maintaining appropriate levels of both Smad4 and beta-catenin. (C)2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available